Short‐term visual acuity 20/40 or better ≤ 2 weeks after treatment · people with traumatic hyphema
Systemic tranexamic acid showed no clear difference in short‐term visual acuity 20/40 or better ≤ 2 weeks after treatment compared with control (moderate certainty).
1 finding from 1 review
Medium‐term visual acuity 20/40 or better > 2 weeks and ≤ 2 months after treatment · people with traumatic hyphema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Long‐term visual acuity 20/40 or better > 2 months after treatment · people with traumatic hyphema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Final visual acuity 20/40 or better at resolution of hyphema · people with traumatic hyphema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to resolution of primary hemorrhage · people with traumatic hyphema
1 finding from 1 review
Secondary hemorrhage at any time point · people with traumatic hyphema
Systemic tranexamic acid may leads to lower secondary hemorrhage at any time point compared with control (low certainty).
1 finding from 1 review
Nausea · people with traumatic hyphema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Blood transfusion · Percutaneous nephrolithotomy
Systemic TXA probably leads to lower blood transfusion compared with no TXA (placebo or usual care) (moderate certainty).
1 finding from 1 review
Stone‐free rate · Percutaneous nephrolithotomy
Systemic TXA showed no clear difference in stone‐free rate compared with no TXA (placebo or usual care) (low certainty).
1 finding from 1 review
Thromboembolic events · Percutaneous nephrolithotomy
1 finding from 1 review
Adverse events · Percutaneous nephrolithotomy
Systemic TXA showed no clear difference in adverse events compared with no TXA (placebo or usual care) (low certainty).
1 finding from 1 review
Secondary interventions · Percutaneous nephrolithotomy
Systemic TXA showed no clear difference in secondary interventions compared with no TXA (placebo or usual care) (low certainty).
1 finding from 1 review
Major surgical complications · Percutaneous nephrolithotomy
Systemic TXA probably leads to lower major surgical complications compared with no TXA (placebo or usual care) (moderate certainty).
1 finding from 1 review
Minor surgical complications · Percutaneous nephrolithotomy
Systemic TXA showed no clear difference in minor surgical complications compared with no TXA (placebo or usual care) (low certainty).
1 finding from 1 review
Unplanned hospitalizations or readmissions · Percutaneous nephrolithotomy
It is very uncertain whether systemic TXA changes unplanned hospitalizations or readmissions compared with no TXA (placebo or usual care) (very low certainty).
1 finding from 1 review
Length of hospital stay · Percutaneous nephrolithotomy
1 finding from 1 review